What is Levofloxacin?
Levofloxacin injection is used to treat bacterial infections in many different parts of the body. It is also used to prevent an anthrax infection after a person has been exposed to anthrax. Levofloxacin is also used to treat and prevent plague (including pneumonic and septicemic plague).
Levofloxacin belongs to the class of medicines known as quinolone antibiotics. It works by killing bacteria or preventing their growth. However, Levofloxacin will not work for colds, flu, or other virus infections.
Levofloxacin is to be given only by or under the direct supervision of your doctor.
To reduce the development of drug-resistant bacteria and maintain the effectiveness of Levofloxacin and other antibacterial drugs, Levofloxacin should be used only to treat or prevent infections that are proven or strongly suspected to be caused by susceptible bacteria. When culture and susceptibility information are available, they should be considered in selecting or modifying antibacterial therapy. In the absence of such data, local epidemiology and susceptibility patterns may contribute to the empiric selection of therapy.
Oral Solution are indicated for the treatment of adults (≥18 years of age) with mild, moderate, and severe infections caused by susceptible isolates of the designated microorganisms in the conditions listed in this section.
Culture and susceptibility testing
Appropriate culture and susceptibility tests should be performed before treatment in order to isolate and identify organisms causing the infection and to determine their susceptibility to Levofloxacin. Therapy with Levofloxacin may be initiated before results of these tests are known; once results become available, appropriate therapy should be selected.
As with other drugs in this class, some isolates of Pseudomonas aeruginosa may develop resistance fairly rapidly during treatment with Levofloxacin. Culture and susceptibility testing performed periodically during therapy will provide information about the continued susceptibility of the pathogens to the antimicrobial agent and also the possible emergence of bacterial resistance.
Levofloxacin is indicated for the treatment of nosocomial pneumonia due to methicillin-susceptible Staphylococcus aureus, Pseudomonas aeruginosa, Serratia marcescens, Escherichia coli, Klebsiella pneumoniae, Haemophilus influenzae, or Streptococcus pneumoniae. Adjunctive therapy should be used as clinically indicated. Where Pseudomonas aeruginosa is a documented or presumptive pathogen, combination therapy with an anti-pseudomonal β-lactam is recommended.
Community-Acquired Pneumonia: 7–14 day Treatment Regimen
Levofloxacin is indicated for the treatment of community-acquired pneumonia due to methicillin-susceptible Staphylococcus aureus, Streptococcus pneumoniae (including multi-drug-resistant Streptococcus pneumoniae [MDRSP]), Haemophilus influenzae, Haemophilus parainfluenzae, Klebsiella pneumoniae, Moraxella catarrhalis, Chlamydophila pneumoniae, Legionella pneumophila, or Mycoplasma pneumoniae.
MDRSP isolates are isolates resistant to two or more of the following antibacterials: penicillin (MIC ≥2 mcg/mL), 2nd generation cephalosporins, e.g., cefuroxime, macrolides, tetracyclines and trimethoprim/sulfamethoxazole.
Community-Acquired Pneumonia: 5-day Treatment Regimen
Levofloxacin is indicated for the treatment of community-acquired pneumonia due to Streptococcus pneumoniae (excluding multi-drug-resistant isolates [MDRSP]), Haemophilus influenzae, Haemophilus parainfluenzae, Mycoplasma pneumoniae, or Chlamydophila pneumoniae.
Acute Bacterial Sinusitis: 5-day and 10–14 day Treatment Regimens
Levofloxacin is indicated for the treatment of acute bacterial sinusitis due to Streptococcus pneumoniae, Haemophilus influenzae, or Moraxella catarrhalis.
Acute Bacterial Exacerbation of Chronic Bronchitis
Levofloxacin is indicated for the treatment of acute bacterial exacerbation of chronic bronchitis due to methicillin-susceptible Staphylococcus aureus, Streptococcus pneumoniae, Haemophilus influenzae, Haemophilus parainfluenzae, or Moraxella catarrhalis.
Complicated Skin and Skin Structure Infections
Levofloxacin is indicated for the treatment of complicated skin and skin structure infections due to methicillin-susceptible Staphylococcus aureus, Enterococcus faecalis, Streptococcus pyogenes, or Proteus mirabilis.
Uncomplicated Skin and Skin Structure Infections
Levofloxacin is indicated for the treatment of uncomplicated skin and skin structure infections (mild to moderate) including abscesses, cellulitis, furuncles, impetigo, pyoderma, wound infections, due to methicillin-susceptible Staphylococcus aureus, or Streptococcus pyogenes.
Chronic Bacterial Prostatitis
Levofloxacin is indicated for the treatment of chronic bacterial prostatitis due to Escherichia coli, Enterococcus faecalis, or methicillin-susceptible Staphylococcus epidermidis.
Complicated Urinary Tract Infections: 5-day Treatment Regimen
Levofloxacin is indicated for the treatment of complicated urinary tract infections due to Escherichia coli, Klebsiella pneumoniae, or Proteus mirabilis.
Complicated Urinary Tract Infections: 10-day Treatment Regimen
Levofloxacin is indicated for the treatment of complicated urinary tract infections (mild to moderate) due to Enterococcus faecalis, Enterobacter cloacae, Escherichia coli, Klebsiella pneumoniae, Proteus mirabilis, or Pseudomonas aeruginosa.
Acute Pyelonephritis: 5 or 10-day Treatment Regimen
Levofloxacin is indicated for the treatment of acute pyelonephritis caused by Escherichia coli, including cases with concurrent bacteremia.
Uncomplicated Urinary Tract Infections
Levofloxacin is indicated for the treatment of uncomplicated urinary tract infections (mild to moderate) due to Escherichia coli, Klebsiella pneumoniae, or Staphylococcus saprophyticus.
Inhalational Anthrax (Post-Exposure)
Levofloxacin is indicated for inhalational anthrax (post-exposure) to reduce the incidence or progression of disease following exposure to aerosolized Bacillus anthracis. The effectiveness of Levofloxacin is based on plasma concentrations achieved in humans, a surrogate endpoint reasonably likely to predict clinical benefit. Levofloxacin has not been tested in humans for the post-exposure prevention of inhalation anthrax. The safety of Levofloxacin in adults for durations of therapy beyond 28 days or in pediatric patients for durations of therapy beyond 14 days has not been studied. Prolonged Levofloxacin therapy should only be used when the benefit outweighs the risk.
Levofloxacin is indicated for treatment of plague, including pneumonic and septicemic plague, due to Yersinia pestis (Y. pestis) and prophylaxis for plague in adults and pediatric patients, 6 months of age and older. Efficacy studies of Levofloxacin could not be conducted in humans with plague for ethical and feasibility reasons. Therefore, approval of this indication was based on an efficacy study conducted in animals.
How should I use Levofloxacin?
Use Levofloxacin solution as directed by your doctor. Check the label on the medicine for exact dosing instructions.
- Levofloxacin solution comes with an extra patient information sheet called a Medication Guide. Read it carefully. Read it again each time you get Levofloxacin solution refilled.
- Take Levofloxacin solution by mouth on an empty stomach at least 1 hour before or 2 hours after eating.
- Use a measuring device marked for medicine dosing. Ask your pharmacist for help if you are unsure of how to measure your dose.
- Drinking extra fluids while you are taking Levofloxacin solution is recommended. Check with your doctor for instructions.
- Do not take a product that has magnesium, aluminum, calcium, zinc, or iron in it within 2 hours before or 2 hours after you take Levofloxacin solution. Examples of these products include certain antacids, multivitamins, quinapril, and calcium-fortified orange juice. Check with your doctor or pharmacist if you have a question about whether you should separate Levofloxacin solution from a certain food or product.
- If you also take sucralfate or didanosine, do not take them within 2 hours before or 2 hours after taking Levofloxacin solution. Check with your doctor if you have questions.
- Levofloxacin solution works best if it is taken at the same time each day.
- To clear up your infection completely, take Levofloxacin solution for the full course of treatment. Keep taking it even if you feel better in a few days.
- Do not miss any doses of Levofloxacin solution. If you miss a dose of Levofloxacin solution, take it as soon as you remember. If it is almost time for your next dose, skip the missed dose and go back to your regular dosing schedule. Do not take 2 doses at once or more than 1 dose in 1 day.
Ask your health care provider any questions you may have about how to use Levofloxacin solution.
Uses of Levofloxacin in details
Levofloxacin is used to treat bacterial infections of the respiratory tract, urinary tract, ear, tooth and prostate gland. It is also used to treat skin and soft tissue infections, anthrax and plague.
Each tablet contains Levofloxacin 250 mg as active ingredient corresponding to Levofloxacin hemihydrate 256.23 mg.
Levofloxacin also contains the following inactive ingredients: Sodium chloride; sodium hydroxide; hydrochloric acid (qs: pH 4.8) and water for injection for a volume of 100 mL (Na+ concentration: 154 mmol/L).
Levofloxacin is a synthetic broad-spectrum antibacterial agent for oral and IV administration. Chemically, Levofloxacin, a chiral fluorinated carboxyquinolone, is the pure (-)-(S)-enantiomer of the racemic drug substance ofloxacin. Levofloxacin is (-)-(S)-9-fluoro-2,3-dihydro-3-methyl-10-(4-methyl-1-piperazinyl)-7-oxo-7H-pyrido[1,2,3-de]-1,4 benzoxazine-6-carboxylic acid hemihydrate.
Its empirical formula is C18H20FN3O4·½H2O and its molecular weight is 370.38.
Levofloxacin is a light yellowish-white to yellow-white crystal or crystalline powder. The molecule exists as a zwitterion at the pH conditions in the small intestine. The data demonstrate that from pH 0.6-5.8, the solubility of Levofloxacin is essentially constant (approximately 100 mg/mL). Levofloxacin is considered soluble to freely soluble in this pH range, as defined by USP nomenclature. Above pH 5.8, the solubility increases rapidly to its maximum at pH 6.7 (272 mg/mL) and is considered freely soluble in this range. Above pH 6.7, the solubility decreases and reaches a minimum value (about 50 mg/mL) at a pH of approximately 6.9. Levofloxacin has the potential to form stable coordination compounds with many metal ions. This in vitro chelation potential has the following formation order: A1+3 > Cu+2 > Zn+2 > Mg+2 > Ca+2.
Dosage in Adult Patients with Normal Renal Function
The usual dose of Levofloxacin Tablets, USP is 250 mg, 500 mg, or 750 mg administered orally every 24 hours, as indicated by infection and described in Table 1.
These recommendations apply to patients with creatinine clearance ≥ 50 mL/min. For patients with creatinine clearance <50 mL/min, adjustments to the dosing regimen are required.
Dosage in Pediatric Patients
The dosage in pediatric patients ≥ 6 months of age is described below in Table 2.
Dosage Adjustment in Adults with Renal Impairment
Administer Levofloxacin Tablets, USP with caution in the presence of renal insufficiency. Careful clinical observation and appropriate laboratory studies should be performed prior to and during therapy since elimination of Levofloxacin may be reduced.
No adjustment is necessary for patients with a creatinine clearance ≥ 50 mL/min.
In patients with impaired renal function (creatinine clearance <50 mL/min), adjustment of the dosage regimen is necessary to avoid the accumulation of Levofloxacin due to decreased clearance.
Table 3 shows how to adjust dose based on creatinine clearance.
Drug Interaction With Chelation Agents: Antacids, Sucralfate, Metal Cations, Multivitamins
Levofloxacin Tablets, USP should be administered at least two hours before or two hours after antacids containing magnesium, aluminum, as well as sucralfate, metal cations such as iron, and multivitamin preparations with zinc or didanosine chewable/buffered tablets or the pediatric powder for oral solution.
Food and Levofloxacin Tablets, USP
Levofloxacin Tablets, USP can be administered without regard to food.
Hydration for Patients Receiving Levofloxacin Tablets, USP
Adequate hydration of patients receiving oral Levofloxacin Tablets, USP should be maintained to prevent the formation of highly concentrated urine. Crystalluria and cylindruria have been reported with quinolones.
There are no data concerning an interaction of quinolones IV with oral antacids, sucralfate, multivitamins, didanosine or metal cations. However, no quinolone should be co-administered with any solution containing multivalent cations eg, magnesium, through the same IV line.
Theophylline: No significant effect of Levofloxacin on the plasma concentrations, AUC and other disposition parameters for theophylline was detected in a clinical study involving 14 healthy volunteers. Similarly, no apparent effect of theophylline on Levofloxacin absorption and disposition was observed. However, concomitant administration of other quinolones with theophylline has resulted in prolonged elimination half-life, elevated serum theophylline levels and a subsequent increase in the risk of theophylline-related adverse reactions in the patient population. Therefore, theophylline levels should be closely monitored and appropriate dosage adjustments made when Levofloxacin is co-administered. Adverse reactions, including seizures, may occur with or without an elevation in serum theophylline levels.
Warfarin: No significant effect of Levofloxacin on the Cmax, AUC and other disposition parameters for R- and S-warfarin was detected in a clinical study involving healthy volunteers. Similarly, no apparent effect of warfarin on Levofloxacin absorption and disposition was observed. There have been reports during the postmarketing experience in patients that Levofloxacin enhances the effects of warfarin. Elevations of the prothrombin time in the setting of concurrent warfarin and Levofloxacin use have been associated with episodes of bleeding. Prothrombin time, INR or other suitable anticoagulation tests should be closely monitored if Levofloxacin is administered concomitantly with warfarin. Patients should also be monitored for evidence of bleeding.
Cyclosporine: No significant effect of Levofloxacin on the Cmax, AUC and other disposition parameters for cyclosporine was detected in a clinical study involving healthy volunteers. However, elevated serum levels of cyclosporine have been reported in the patient population when co-administered with some other quinolones. Levofloxacin Cmax and ke were slightly lower while Tmax and t½ were slightly longer in the presence of cyclosporine than those observed in other studies without concomitant medication. The differences, however, are not considered to be clinically significant. Therefore, no dosage adjustment is required for Levofloxacin or cyclosporine when administered concomitantly.
Digoxin: No significant effect of Levofloxacin on the Cmax, AUC and other disposition parameters for digoxin was detected in a clinical study involving healthy volunteers. Levofloxacin absorption and disposition kinetics were similar in the presence or absence of digoxin. Therefore, no dosage adjustment for Levofloxacin or digoxin is required when administered concomitantly.
Probenecid and Cimetidine: No significant effect of probenecid or cimetidine on the rate and extent of Levofloxacin absorption were observed in a clinical study involving healthy volunteers. The AUC and t1/2 of Levofloxacin were 27-38% and 30% higher, respectively, while CL/F and CLR were 21-35% lower during concomitant treatment with probenecid or cimetidine compared to Levofloxacin alone. Although these differences were statistically significant, the changes were not high enough to warrant dosage adjustment for Levofloxacin when probenecid or cimetidine is co-administered.
Nonsteroidal Anti-Inflammatory Drugs: The concomitant administration of a nonsteroidal anti-inflammatory drug with a quinolone, including Levofloxacin, may increase the risk of CNS stimulation and convulsive seizures.
Antidiabetic Agents: Disturbances of blood glucose, including hyperglycemia and hypoglycemia, have been reported in patients treated concomitantly with quinolones and an antidiabetic agent. Therefore, careful monitoring of blood glucose is recommended when these agents are co-administered.
Levofloxacin side effects
Serious and Otherwise Important Adverse Reactions
The following serious and otherwise important adverse drug reactions are discussed in greater detail in other sections of labeling:
- Tendon Effects
- Exacerbation of Myasthenia Gravis
- Hypersensitivity Reactions
- Other Serious and Sometimes Fatal Reactions
- Central Nervous System Effects
- Clostridium difficile-Associated Diarrhea
- Peripheral Neuropathy that may be irreversible
- Prolongation of the QT Interval
- Musculoskeletal Disorders in Pediatric Patients
- Blood Glucose Disturbances
- Photosensitivity/Phototoxicity [see
- Development of Drug Resistant Bacteria
Hypotension has been associated with rapid or bolus intravenous infusion of Levofloxacin. Levofloxacin should be infused slowly over 60 to 90 minutes, depending on dosage.
Crystalluria and cylindruria have been reported with quinolones, including Levofloxacin. Therefore, adequate hydration of patients receiving Levofloxacin should be maintained to prevent the formation of a highly concentrated urine.
Clinical Trial Experience
Because clinical trials are conducted under widely varying conditions, adverse reaction rates observed in the clinical trials of a drug cannot be directly compared to rates in the clinical trials of another drug and may not reflect the rates observed in practice.
The data described below reflect exposure to Levofloxacin in 7537 patients in 29 pooled Phase 3 clinical trials. The population studied had a mean age of 50 years (approximately 74% of the population was < 65 years of age), 50% were male, 71% were Caucasian, 19% were Black. Patients were treated with Levofloxacin for a wide variety of infectious diseases. Patients received Levofloxacin doses of 750 mg once daily, 250 mg once daily, or 500 mg once or twice daily. Treatment duration was usually 3 to 14 days, and the mean number of days on therapy was 10 days.
The overall incidence, type and distribution of adverse reactions was similar in patients receiving Levofloxacin doses of 750 mg once daily, 250 mg once daily, and 500 mg once or twice daily. Discontinuation of Levofloxacin due to adverse drug reactions occurred in 4.3% of patients overall, 3.8% of patients treated with the 250 mg and 500 mg doses and 5.4% of patients treated with the 750 mg dose. The most common adverse drug reactions leading to discontinuation with the 250 and 500 mg doses were gastrointestinal (1.4%), primarily nausea (0.6%); vomiting (0.4%); dizziness (0.3%); and headache (0.2%). The most common adverse drug reactions leading to discontinuation with the 750 mg dose were gastrointestinal (1.2%), primarily nausea (0.6%), vomiting (0.5%); dizziness (0.3%); and headache (0.3%).
Adverse reactions occurring in ≥1% of levofloxacin-treated patients and less common adverse reactions, occurring in 0.1 to <1% of levofloxacin-treated patients, are shown in Table 6 and Table 7, respectively. The most common adverse drug reactions (≥3%) are nausea, headache, diarrhea, insomnia, constipation, and dizziness.
In clinical trials using multiple-dose therapy, ophthalmologic abnormalities, including cataracts and multiple punctate lenticular opacities, have been noted in patients undergoing treatment with quinolones, including Levofloxacin. The relationship of the drugs to these events is not presently established.
Table 8 lists adverse reactions that have been identified during post-approval use of Levofloxacin. Because these reactions are reported voluntarily from a population of uncertain size, reliably estimating their frequency or establishing a causal relationship to drug exposure is not always possible.
Patients hypersensitive to Levofloxacin or any other quinolones or any excipients of Levofloxacin. Patients with epilepsy and those with history of tendon disorder related to fluoroquinolone administration.
Use in pregnancy: Levofloxacin caused no impairment of fertility or reproductive performance in rats at oral doses as high as 360 mg/kg/day. It was not teratogenic in rats at oral doses as high as 810 mg/kg/day or at IV dose up to 160 mg/kg/day. No teratogenicity was observed when rabbits were dosed orally as high as 50 mg/kg/day.
In the absence of human data and due to the experimental risk of damage by fluoroquinolones to the weight-bearing cartilage of the growing organism, Levofloxacin must not be used in pregnant women or women suspected of being pregnant.
Use in lactation: In the absence of human data and due to the experimental risk of damage by fluoroquinolones to the weight-bearing cartilage of the growing organism, Levofloxacin must not be used in breastfeeding women.
Use in children: Safety and effectiveness in pediatric patients and adolescents <16 years have not been established. Quinolones, including Levofloxacin, cause arthropathy and osteochondrosis in juvenile animals of several species.
Elderly: The pharmacokinetic properties of Levofloxacin in younger adults and elderly do not differ significantly when creatinine clearance is taken into consideration. However, since Levofloxacin is known to be substantially excreted by the kidney, the risk of toxic reactions to Levofloxacin may be greater in patients with impaired renal function. Because elderly patients are more likely to have decreased renal function, care should be taken in dose selection and it may be useful to monitor renal function.
Active ingredient matches for Levofloxacin:
|Unit description / dosage (Manufacturer)||Price, USD|
|Tablet; Oral; Levofloxacin 250 mg|
|Tablet; Oral; Levofloxacin 500 mg|
|Tablet; Oral; Levofloxacin 750 mg|
|Tablet, Film-Coated; Oral; Levofloxacin Hemihydrate 250 mg|
|Tablet, Film-Coated; Oral; Levofloxacin Hemihydrate 500 mg|
|Injectable; Injection; Levofloxacin 25 mg / ml|
|Solution; Ophthalmic; Levofloxacin 0.5%|
|Injectable; Injection; Levofloxacin 5 mg / ml|
|Iquix 1.5% Solution 5ml Bottle||$ 81.68|
|Levofloxacin hemihydr 100% powder||$ 42.69|
|Levaquin 750 mg tablet||$ 28.06|
|Levaquin 750 mg leva-pak tablet||$ 27.51|
|Levaquin 500 mg tablet||$ 16.57|
|Iquix 1.5% eye drops||$ 15.71|
|Levaquin 250 mg tablet||$ 13.71|
|Quixin 0.5% eye drops||$ 12.21|
|Quixin 0.5% Solution||$ 11.40|
|Levaquin i.v. 25 mg/ml vial||$ 1.94|
|Levaquin 500 mg/100 ml d5w||$ 0.44|
|Levofloxacin 500 mg|
|Tablets; Oral; Levofloxacin 250 mg|
|Tablets; Oral; Levofloxacin 500 mg|
|Tablets; Oral; Levofloxacin 750 mg|
|Tablets, Film-Coated; Oral; Levofloxacin Hemihydrate 250 mg|
|Tablets, Film-Coated; Oral; Levofloxacin Hemihydrate 500 mg|
|Solution; Oral; Levofloxacin 25 mg / ml|
|Levofloxacin tablet 250 mg (Cobalt Pharmaceuticals Company (Canada))|
|Levofloxacin tablet 500 mg (Pro Doc Limitee (Canada))|
|Levofloxacin tablet 750 mg (Cobalt Pharmaceuticals Company (Canada))|
|Levofloxacin tablet, film coated 250 mg/1 (REMEDYREPACK INC. (US))|
|Levofloxacin tablet, film coated 500 mg/1 (Zydus Pharmaceuticals (USA, US) Inc.)|
|Levofloxacin tablet 500 mg/1 (Wockhardt Limited (US))|
|Levofloxacin injection, solution 5 mg/mL (Sandoz Inc (US))|
|Levofloxacin tablet 250 mg/1 (Aidarex Pharmaceuticals LLC (US))|
|Levofloxacin tablet 750 mg/1 (Wockhardt USA LLC. (US))|
|Levofloxacin tablet, film coated 750 mg/1 (Major Pharmaceuticals (US))|
|Levofloxacin solution/ drops 5 mg/mL (PACK Pharmaceuticals, LLC (US))|
|Levofloxacin injection, solution 750 mg/150mL (Auro Medics Pharma Llc (US))|
|Levofloxacin injection, solution 500 mg/100mL (West Ward Pharmaceuticals Corp (US))|
|Levofloxacin injection, solution, concentrate 500 mg/20mL (Auro Medics Pharma Llc (US))|
|Levofloxacin injection 5 mg/mL (Fresenius Kabi USA, LLC (US))|
|Levofloxacin solution 25 mg/mL (Department Of State Health Services, Pharmacy Branch (US))|
|Levofloxacin injection, solution 250 mg/50mL (West Ward Pharmaceuticals Corp (US))|
|Levofloxacin solution 5 mg/mL (Akorn Inc. (US))|
|Levofloxacin injection, solution, concentrate 750 mg/30mL (Auro Medics Pharma Llc (US))|
|Levofloxacin injection, solution 25 mg/mL (Claris Lifesciences Inc. (US))|
|Levofloxacin injection 25 mg/mL (Heritage Pharmaceuticals Inc. (US))|
List of Levofloxacin substitutes (brand and generic names):
|Levofloxacin - 1 A Pharma (Germany)|
|Levofloxacin 0.5.% Amel (Japan)|
|Levofloxacin 0.5.% CH (Japan)|
|Levofloxacin 0.5.% FFP (Japan)|
|Levofloxacin 0.5.% JG (Japan)|
|Levofloxacin 0.5.% Kaken (Japan)|
|Levofloxacin 0.5.% Kissei (Japan)|
|Levofloxacin 0.5.% KOG (Japan)|
|Levofloxacin 0.5.% Kyorin (Japan)|
|Levofloxacin 0.5.% Mylan (Japan)|
|Levofloxacin 0.5.% Nichi-Iko (Japan)|
|Levofloxacin 0.5.% Nipro (Japan)|
|Levofloxacin 0.5.% Nisshin (Japan)|
|Levofloxacin 0.5.% Nitten (Japan)|
|Levofloxacin 0.5.% NP (Japan)|
|Levofloxacin 0.5.% Ohara (Japan)|
|Levofloxacin 0.5.% Pfizer (Japan)|
|Levofloxacin 0.5.% Takata (Japan)|
|Levofloxacin 0.5.% TOA (Japan)|
|Levofloxacin 0.5.% Towa (Japan)|
|Levofloxacin 0.5.% TS (Japan)|
|Levofloxacin 0.5.% TYK (Japan)|
|Levofloxacin 0.5.% Wakamoto (Japan)|
|Levofloxacin 0.5.% YD (Japan)|
|Levofloxacin 1.5.% Amel (Japan)|
|Levofloxacin 1.5.% FFP (Japan)|
|Levofloxacin 1.5.% JG (Japan)|
|Levofloxacin 1.5.% Kaken (Japan)|
|Levofloxacin 1.5.% Kissei (Japan)|
|Levofloxacin 1.5.% KOG (Japan)|
|Levofloxacin 1.5.% Kyorin (Japan)|
|Levofloxacin 1.5.% Nipro (Japan)|
|Levofloxacin 1.5.% Nitten (Japan)|
|Levofloxacin 1.5.% Ohara (Japan)|
|Levofloxacin 1.5.% Pfizer (Japan)|
|Levofloxacin 1.5.% Takata (Japan)|
|Levofloxacin 1.5.% Teva (Japan)|
|Levofloxacin 1.5.% TOA (Japan)|
|Levofloxacin 1.5.% TS (Japan)|
- DailyMed. "LEVOFLOXACIN: DailyMed provides trustworthy information about marketed drugs in the United States. DailyMed is the official provider of FDA label information (package inserts).". https://dailymed.nlm.nih.gov/dailyme... (accessed September 17, 2018).
- PubChem. "LEVOFLOXACIN". https://pubchem.ncbi.nlm.nih.gov/com... (accessed September 17, 2018).
- DrugBank. "LEVOFLOXACIN". http://www.drugbank.ca/drugs/DB01137 (accessed September 17, 2018).
- DTP/NCI. "LEVOFLOXACIN: The NCI Development Therapeutics Program (DTP) provides services and resources to the academic and private-sector research communities worldwide to facilitate the discovery and development of new cancer therapeutic agents.". https://dtp.cancer.gov/dtpstandard/s... (accessed September 17, 2018).
- Wikipedia. "levofloxacin anhydrous: Link to the compound information in Wikipedia.". https://en.wikipedia.org/wiki/Levofl... (accessed September 17, 2018).
ReviewsThe results of a survey conducted on ndrugs.com for Levofloxacin are given in detail below. The results of the survey conducted are based on the impressions and views of the website users and consumers taking Levofloxacin. We implore you to kindly base your medical condition or therapeutic choices on the result or test conducted by a physician or licensed medical practitioners.
3 consumers reported age
There are no reviews yet. Be the first to write one!
Information checked by Dr. Sachin Kumar, MD Pharmacology